MYCN and neoplasm: A variety of somatic mutations in oncogenic pathways have been described, for example, amplification of the MYCN gene and mutation in the ALK and ATRX genes [4, 5, 6, 7] MYCN gene amplification occurs in about 25% of tumours and is a common feature of high‐risk disease, with rapid disease progression and poor prognosis; abnormal MYCN expression is the strongest predictor of poor prognosis [8].